Barclays PLC Gilead Sciences, Inc. Call Options Transaction History

Barclays PLC

$377 Billion
Q3 2024

Call Options

25 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 15, 2024	SELL	$66.59 - $83.99 $7.97 Million - $10.1 Million	-119,700 Reduced 51.09%	114,600 $9.61 Million
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $10.8 Million - $12.5 Million	171,032 Added 270.33%	234,300 $16.1 Million
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $2.87 Million - $3.5 Million	-40,132 Reduced 38.81%	63,268 $4.64 Million
Q4 2023 Feb 15, 2024	BUY	$73.27 - $83.09 $3.71 Million - $4.2 Million	50,600 Added 95.83%	103,400 $8.38 Million
Q3 2023 Nov 07, 2023	SELL	$73.94 - $80.67 $8.99 Million - $9.81 Million	-121,600 Reduced 69.72%	52,800 $3.96 Million
Q2 2023 Aug 03, 2023	BUY	$76.01 - $86.7 $9.67 Million - $11 Million	127,200 Added 269.49%	174,400 $13.4 Million
Q1 2023 May 04, 2023	SELL	$77.31 - $88.08 $12.6 Million - $14.4 Million	-163,200 Reduced 77.57%	47,200 $3.92 Million
Q4 2022 Feb 13, 2023	BUY	$62.32 - $89.47 $13.1 Million - $18.8 Million	210,400 New	210,400 $18.1 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $6.07 Million - $6.89 Million	93,500 Added 53.86%	267,100 $19.4 Million
Q3 2021 Nov 09, 2021	BUY	$67.69 - $73.03 $6.6 Million - $7.12 Million	97,500 Added 128.12%	173,600 $12.1 Million
Q2 2021 Aug 13, 2021	SELL	$63.47 - $69.35 $4.31 Million - $4.71 Million	-67,900 Reduced 47.15%	76,100 $5.24 Million
Q1 2021 May 13, 2021	SELL	$60.0 - $68.46 $16.4 Million - $18.7 Million	-272,500 Reduced 65.43%	144,000 $9.31 Million
Q3 2020 Nov 12, 2020	BUY	$62.1 - $78.08 $17.8 Million - $22.4 Million	286,600 Added 220.63%	416,500 $26.3 Million
Q2 2020 Aug 12, 2020	SELL	$72.34 - $84.0 $34.9 Million - $40.5 Million	-482,100 Reduced 78.77%	129,900 $10 Million
Q1 2020 May 13, 2020	SELL	$62.63 - $80.22 $27.7 Million - $35.5 Million	-442,500 Reduced 41.96%	612,000 $45.8 Million
Q4 2019 Feb 10, 2020	BUY	$61.62 - $67.78 $36.8 Million - $40.5 Million	597,100 Added 130.54%	1,054,500 $68.5 Million
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $8.15 Million - $8.99 Million	130,300 Added 39.83%	457,400 $29 Million
Q2 2019 Aug 14, 2019	SELL	$61.87 - $69.38 $4.16 Million - $4.66 Million	-67,200 Reduced 17.04%	327,100 $22.1 Million
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $869,167 - $973,695	13,900 Added 3.65%	394,300 $25.6 Million
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $18.8 Million - $24.5 Million	-310,000 Reduced 44.9%	380,400 $23.8 Million
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $12.8 Million - $14.1 Million	178,900 Added 34.98%	690,400 $53.3 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $5.51 Million - $6.43 Million	-84,900 Reduced 14.24%	511,500 $36.2 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $12.8 Million - $15.6 Million	176,200 Added 41.93%	596,400 $45 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $11.9 Million - $14 Million	-167,600 Reduced 28.51%	420,200 $30.1 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $42.4 Million - $50.2 Million	587,800	587,800 $47.6 Million

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$10.9 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.4 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$6.9 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.57 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.43 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account